Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis.

IF 4.2 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-09-19 DOI:10.1007/s13555-025-01519-7

Sonja Ständer, Gil Yosipovitch, Brian S Kim, Martin Steinhoff, April Armstrong, Franz J Legat, Kenji Kabashima, Takeshi Nakahara, Atsuyuki Igarashi, Amy H Praestgaard, Tien V Nguyen, Mike Bastian

{"title":"Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis.","authors":"Sonja Ständer, Gil Yosipovitch, Brian S Kim, Martin Steinhoff, April Armstrong, Franz J Legat, Kenji Kabashima, Takeshi Nakahara, Atsuyuki Igarashi, Amy H Praestgaard, Tien V Nguyen, Mike Bastian","doi":"10.1007/s13555-025-01519-7","DOIUrl":null,"url":null,"abstract":"Introduction: Itch control is an important treatment goal for patients with atopic dermatitis (AD). According to the treat-to-target framework, optimal treatment goals in AD were defined for various disease domains (e.g., achievement of Eczema Area and Severity Index [EASI] ≤ 7, Peak Pruritus Numeric Rating Scale [PP-NRS] ≤ 4, and Dermatology Life Quality Index [DLQI] ≤ 5) to be achieved after 6 months and sustained thereafter.Methods: In this post hoc analysis of LIBERTY AD CHRONOS (NCT02260986), we report the proportion of patients achieving an optimal itch response with or without an optimal response in signs (EASI ≤ 7) and quality of life (DLQI ≤ 5), after 24 and 52 weeks of treatment with dupilumab.Results: The majority of patients (69 of 90; 76.7%) had an optimal itch response at week 24 as measured by treat-to-target goal PP-NRS ≤ 4; this proportion was sustained at week 52 (64 of 79; 81.0%). Using SCORing Atopic Dermatitis (SCORAD) Pruritus Visual Analog Scale (VAS) < 4 as validation, the majority of patients (76/89; 85.4%) had an optimal itch response at week 24, and this proportion was also sustained at week 52 (69 of 79; 87.3%). Around 70% of patients with an optimal itch response according to PP-NRS or SCORAD Pruritus VAS also had optimal response in EASI and DLQI at weeks 24 and 52.Conclusion: Dupilumab provided optimal itch response and further optimal treatment response in signs and quality of life at week 24, sustained up to 52 weeks, in the majority of patients. Graphical Abstract available for this article.Trial registration: NCT02260986.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01519-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Itch control is an important treatment goal for patients with atopic dermatitis (AD). According to the treat-to-target framework, optimal treatment goals in AD were defined for various disease domains (e.g., achievement of Eczema Area and Severity Index [EASI] ≤ 7, Peak Pruritus Numeric Rating Scale [PP-NRS] ≤ 4, and Dermatology Life Quality Index [DLQI] ≤ 5) to be achieved after 6 months and sustained thereafter.

Methods: In this post hoc analysis of LIBERTY AD CHRONOS (NCT02260986), we report the proportion of patients achieving an optimal itch response with or without an optimal response in signs (EASI ≤ 7) and quality of life (DLQI ≤ 5), after 24 and 52 weeks of treatment with dupilumab.

Results: The majority of patients (69 of 90; 76.7%) had an optimal itch response at week 24 as measured by treat-to-target goal PP-NRS ≤ 4; this proportion was sustained at week 52 (64 of 79; 81.0%). Using SCORing Atopic Dermatitis (SCORAD) Pruritus Visual Analog Scale (VAS) < 4 as validation, the majority of patients (76/89; 85.4%) had an optimal itch response at week 24, and this proportion was also sustained at week 52 (69 of 79; 87.3%). Around 70% of patients with an optimal itch response according to PP-NRS or SCORAD Pruritus VAS also had optimal response in EASI and DLQI at weeks 24 and 52.

Conclusion: Dupilumab provided optimal itch response and further optimal treatment response in signs and quality of life at week 24, sustained up to 52 weeks, in the majority of patients. Graphical Abstract available for this article.

Trial registration: NCT02260986.

查看原文本刊更多论文

Dupilumab治疗中度至重度特应性皮炎成人的最佳瘙痒反应

瘙痒控制是特应性皮炎（AD）患者的重要治疗目标。根据治疗-目标框架，针对不同疾病领域（如湿疹面积和严重程度指数[EASI]≤7，峰值瘙痒数值评定量表[PP-NRS]≤4，皮肤病生活质量指数[DLQI]≤5）在6个月后达到并持续治疗AD的最佳治疗目标。方法：在这项LIBERTY AD CHRONOS （NCT02260986）的事后分析中，我们报告了在dupilumab治疗24周和52周后，在体征（EASI≤7）和生活质量（DLQI≤5）方面达到最佳瘙痒反应的患者比例。结果：大多数患者（69 / 90,76.7%）在第24周瘙痒反应最佳，治疗-目标目标PP-NRS≤4；这一比例在第52周保持不变（64 / 79;81.0%）。结论：在大多数患者中，杜匹单抗在第24周提供了最佳的瘙痒反应，并在体征和生活质量方面进一步提供了最佳的治疗反应，持续长达52周。本文提供的图形摘要。试验注册：NCT02260986。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.